Wednesday, January 7, 2026 1/7/2026

Development of Next-Generation Blood-to-barcode (B2B) chip for In Vivo CRISPR-Based Discovery of Metastasis Regulators

Award Number: R01CA277507
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/07/2023
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

Development of Next-Generation Blood-to-barcode (B2B) chip for In Vivo CRISPR-Based Discovery of Metastasis Regulators - Project Summary: Widespread dissemination together with emergence of tumor cell resistance to existing therapeutic agents is ultimately responsible for almost 90% of cancer deaths. However, the metastasis-promoting genetic programs and the underlying signaling networks orchestrating the progression of the metastatic disease process remain poorly defined. In order to develop effective anti-metastatic therapeutic agents and improve patient outcomes, further progress elucidating the fundamental biology of metastasis is needed. Notably, majority of the comparative genetic studies to date have relied on the primary tumors and the metastatic lesions to facilitate the identification of genetics factors that drive tumor progression and dissemination. However, deciphering drivers of metastasis solely based on the genetic information from solid tumors is limiting due to genetic divergence and tumor heterogeneity. Since metastatic tumor cells must leave the primary tumor, circulating tumor cells (CTCs) that break free from primary tumors and seed metastatic lesions are better suited to facilitate comprehensive understanding of the metastatic disease process. However, efficient capture of CTCs and unbiased genomic amplification are extremely challenging due to the rarity and fragility of CTCs. Thus, new technologies and platforms are needed to effectively utilize the biology of CTCs for systematic identification of metastasis-promoting genetic factors. Recently we reported the very first genome-scale in vivo CTC CRISPR knockout screen specifically designed to identify genetic-factors contributing to tumor cell dissemination. Xenografted tumors were seeded with pooled CRISPR-edited metastatic prostate cancer cells, each harboring single gene loss-of-function genetic alterations covering all protein coding genes of the human genome. Using a high-performance microfluidic immunomagnetic cell sorting approach for efficient CTC capture directly from mouse blood coupled with next-generation sequencing (NGS) for barcoded guide RNA enrichment analysis, we demonstrated the feasibility and reliability of the use of CTCs for the identification of critical genetic factors promoting tumor cell dissemination thereby illuminating targeted routes for inhibiting metastasis driving pathways. In this project, we will develop a next-generation blood-to-barcode (B2B) chip (Aim1) that accelerates in vivo CRISPR-based discovery efforts to identify critical genetic factors impacting metastatic potential. The B2B chip will power a series of in vivo CRISPR activation screens (Aim2) across a panel of human and mouse metastatic prostate cancer cell lines strategically selected for modeling broad range of tumor metastatic potential in vivo as well as origins of metastatic tumors. Collectively, these screens are anticipated to reveal genetic factors that could be targeted therapeutically to limit the development of metastatic tumors. Through systematic clinical relevancy prioritization and validations using a battery of in vitro and in vivo approaches in prostate cancer model systems (Aim3), clinical utility of our lead genetic factors as targeted anti- metastatic agents will be established.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $625,914 )
2025	2025	NORTHWESTERN UNIVERSITY	633 CLARK ST	EVANSTON	IL	60208	COOK	USA	Cancer Detection and Diagnosis Research	000	3	2/19/2025	NON-COMPETING CONTINUATION	$563,324
2025	2025	NORTHWESTERN UNIVERSITY	633 CLARK ST	EVANSTON	IL	60208	COOK	USA	Cancer Detection and Diagnosis Research	001	3	7/10/2025	NON-COMPETING CONTINUATION	$62,590
														Subtotal = $625,914

Issue Date FY: 2024 ( Subtotal = $594,619 )
2024	2024	NORTHWESTERN UNIVERSITY	633 CLARK ST	EVANSTON	IL	60208	COOK	USA	Cancer Detection and Diagnosis Research	000	2	2/9/2024	NON-COMPETING CONTINUATION	$563,324
2024	2024	NORTHWESTERN UNIVERSITY	633 CLARK ST	EVANSTON	IL	60208	COOK	USA	Cancer Detection and Diagnosis Research	001	2	4/17/2024	NON-COMPETING CONTINUATION	$31,295
														Subtotal = $594,619

Issue Date FY: 2023 ( Subtotal = $625,914 )
2023	2023	NORTHWESTERN UNIVERSITY	633 CLARK	EVANSTON	IL	60208	COOK	USA	Cancer Detection and Diagnosis Research	000	1	2/7/2023	NEW	$625,914
														Subtotal = $625,914

Grand Total All Awards = $1,846,447

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of Next-Generation Blood-to-barcode (B2B) chip for In Vivo CRISPR-Based Discovery of Metastasis Regulators

Award Number: R01CA277507

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/07/2023

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer